Skip to main
CYTXW
CYTXW logo

Cytori Therapeutics Inc Warrants 2016-9.12.18 On Shares (CYTXW)

$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy CYTXW Stock

About Cytori Therapeutics Inc Warrants 2016-9.12.18 On Shares (CYTXW)

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.
Market cap
Today's volume
Revenue (TTM)
Avg. daily volume
EBITDA (TTM)
Open
Price / earnings ratio
Today's range
Debt / equity
52 week range
5 year debt / equity
Beta (LTM)
Interest coverage
Dividend & yield— (—)
Current ratio
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

How to buy CYTXW stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in CYTXW stock

    Navigate to the Explore page. Then, type CYTXW into the search bar. When you see CYTXW stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased CYTXW stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.

Buy CYTXW Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.